Press release

Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets   Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce a research collaboration with Amgen, to develop […]

Funding from Deepbridge Capital, Innovate UK and Scottish Investment Bank will support development of next generation Ophthalmology biologics   Thursday, 16 March 2017: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and […]

BBSRC support for research and commercialisation contributed to the creation of award-winning spin-out company Elasmogen by Dr Caroline Barelle and Professor Andrew Porter at the University of Aberdeen. The company is developing new medicines based on the discovery of certain antibody-like molecules found in sharks. IMPACT SUMMARY University of Aberdeen researchers Dr Caroline Barelle and […]

Aberdeen, UK – [July 2016] OBN announced recently the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain independent and celebrate innovation across the UK life sciences industry and recognise achievements from emerging to late stage R&D companies, as well as life sciences investors. A judging […]

Aberdeen, UK – [27th March 2016] As Europe’s leading biopartnering and investment conference, BioTrinity brings together investors, pharmaceutical executives and innovative life science R&D companies, from around the world. To mark BioTrinity’s 10th anniversary the new Perfect Pitch session has been introduced to their London meeting to increase the number of ways biotechnology companies can […]